KROS

Keros Therapeutics, Inc.

Healthcare
Biotechnology
$355M market cap

Forecast run · Sep 14, 2026Upside rank 1604 of 3,136

Model Signal

ForecastQ Daily Probabilities

33.3%

43.7%

13.7%

Analyst Consensus

Recommendation2.41/5 Buy

Last price$11.08

Price target$20.33

Implied move+83.5%

Analysts17

ForecastQ Portfolios

KROS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.